Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Abbisko Raises $226 Million in Hong Kong IPO for Cancer Therapies

publication date: Oct 15, 2021

Abbisko, a Shanghai biopharma, completed a $226 million IPO in Hong Kong to support its small molecule therapies for cancer. At the IPO price, Abbisko has a $1.1 billion market capitalization. Formed in 2016, Abbisko has developed a portfolio of 14 drug candidates, five of them at clinical stage. Its lead program, a pan-FGFR inhibitor aimed at urothelial carcinoma, is partnered with AstraZeneca. The company plans to start Phase Ib/II China trials for the candidate soon. More details....

Stock Symbol: (HK: 2256)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital